A number of modalities including both pharmaceutical and cell-based treatments have long
been tested and developed to prevent and treat relapses after allogeneic stem cell …

Donor lymphocyte infusions for treatment of relapse after allogeneic bone marrow or stem
cell transplantation is being used with increasing frequency. Study of this form of adoptive …

Donor lymphocyte infusion (DLI) using unstimulated leukapheresis is one of the most
effective treatment strategies for patients with hematological malignancies; its graft-versus …

Abstract Purpose: Donor lymphocyte infusions (DLIs) provide effectivetherapy for patients
with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation …

Introduction: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of
choice for many malignant hematological disorders. Following recent improvements in non …

BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic
peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) …

Simple Summary Allogeneic stem cell transplantation (allo-SCT) represents the only
potentially curative treatment for high-risk acute myeloid leukemia (AML) and …

The results of donor lymphocyte infusion (DLI) for treatment of relapse after bone marrow
transplantation (BMT) are reviewed. Durable complete remission can be achieved at the …

The success of donor lymphocyte infusion (DLI) in treating chronic myeloid leukaemia that
had recurred after allogeneic haematopoietic stem cell transplantation provided direct …

The infusion of lymphocytes from the original marrow donor (donor lymphocyte infusions
[DLI]) is remarkably effective in treating chronic myeloid leukemia in relapse after allogeneic …